echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Treatment or new breakthrough in gastrointestinal mesothelioma (GIST), EMA grants Ilixadencel "orphan drug qualification"

    Treatment or new breakthrough in gastrointestinal mesothelioma (GIST), EMA grants Ilixadencel "orphan drug qualification"

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Gastrointestinal mesothelioma (GIST) is a cancerous (malignant) tumor that is originally caused by a specific class of cells (interstitial precancer cells) in the esophageal, stomach, or intestinal wall.
    most gastrointestinal mesotheliomas are caused by mutations in a cell growth control gene called C-KIT.
    most of these tumors (60 to 70 percent) occur in the stomach, 20 to 25 percent in the small intestine, and a few in the esoesois, colon, and rectum.
    age of diagnosis is 50 to 60 years.
    these tumors usually grow slowly, but some grow faster and spread to other areas.
    pharmaceutical company Immunicum AB recently announced that the European Medicines Agency (EMA) Orphan Drug Products Commission (COMP) awarded the company's candidate drug ilixadencel "orphan drug qualification" for the treatment of gastrointestinal mesothelioma (GIST).
    COMP approval is based on the results of the GIST I/II clinical trial.
    Ilixadencel is a cell-based cancer immunotherapy used to treat solid tumors.
    its active ingredient is an allogeneic tree protrusion cell derived from the activated of healthy blood donors.
    . Sven Rohmann, M.D., chief executive of Immunicum, said, "Both the EMA and the FDA have awarded imaxadencel orphan drug eligibility for GIST adaptation, which is an important step for Immunicum."
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.